Pradaxa Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Pradaxa Bleeding Litigation

New York, New York (PRWEB) March 23, 2014

A status conference will be held on April 9, 2014, to address the thousands of Pradaxa lawsuits ( ) currently pending in a multidistrict litigation underway in U.S. District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. According to court documents, nearly 2,300 claims have been filed in the proceeding on behalf of patients who suffered uncontrollable internal bleeding, allegedly due to Pradaxa. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation MDL No. 2385)

Our Firm hears from Pradaxa patients on a regular basis who allegedly suffered serious episodes of uncontrollable internal bleeding. We are monitoring this litigation closely, says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is offering free and confidential case evaluations to individuals who may have been injured as a result of taking this medication.

Pradaxa Bleeding Allegations

According to court documents, Pradaxa was brought to market in 2010, and was touted as an improvement over warfarin, a blood thinner that has been used for decades. Last month, 7 Action News in Detroit reported Pradaxa may be the most complained about drug in the U.S., after finding that the U.S. Food & Drug Administration (FDA) had received reports of 12,494 injuries and 1,158 deaths among Pradaxa users since the blood thinner was launched in the U.S. No other prescription drug on the market was associated with as many adverse events, the stations investigation found.*

Among other things, plaintiffs in Pradaxa lawsuits claim that Boehringer Ingelheim failed to provide adequate warnings regarding the risk for internal hemorrhaging related to Pradaxa, and wrongly characterized the drug as being equally as safe as warfarin. The lawsuits point out that while warfarin bleeding can be easily stopped via the administration of vitamin K, while there is no readily-available antidote for Pradaxa bleeding.

In December 2013, the FDA announced that it would conduct a new, large-scale assessment to compare Pradaxa bleeding rates with those associated with warfarin.

Alleged victims of Pradaxa bleeding may be entitled to compensation for their injury-related damages. To learn more about filing a Pradaxa lawsuit, please visit Bernstein Liebhard LLPs website, or call 800-511-5092 to schedule a free, no obligation case review.

*, 7 Action News, February 25, 2014

Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016



Leave a Reply